Developments Titan Pharma’s Probuphine implant for long-term maintenance treatment of opioid dependence approved by Health Canada Health Canada has approved the sale of Probuphine, a subdermal implant developed by Titan Pharmaceuticals (NASDAQ:TTNP), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of... April 20, 2018